Table 3 Overview of TEAEs.

From: Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

n (%)

All

(n = 73)

Any TEAE

73 (100)

Grade ≥3 TEAEs

58 (79.5)

Treatment-emergent SAEs

39 (53.4)

Drug-related treatment-emergent SAEs

22 (30.1)

TEAEs leading to deatha

7 (9.6)

TEAEs leading to permanent discontinuation of study treatment

14 (19.2)

TEAEs leading to premature study drug discontinuation

24 (32.9)

  Bortezomib

13 (17.8)

  Lenalidomide

11 (15.1)

  Dexamethasone

4 (5.5)

  1. aTEAEs leading to death included listeremia (n = 1), progressive disease (n = 1), metastatic breast cancer (n = 1), metastatic melanoma (n = 1), COVID-19 (n = 2), diverticulitis (n = 1)
  2. SAE, serious adverse event; TEAE, treatment-emergent adverse event.
Back to article page